🔎 Trials Near Me

Home › Idiopathic Thrombocytopenic Purpura › Massachusetts › Boston

Idiopathic Thrombocytopenic Purpura clinical trials in Boston, MA

6 studies for Idiopathic Thrombocytopenic Purpura are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

RecruitingPhase 3
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 to 80 · All sexes · Updated Sep 14, 2026 · NCT07095127

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

RecruitingPhase 2
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07104565

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

RecruitingPhase 3
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

RecruitingPhase 3
  • Massachusetts General Hospital Cancer Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT07007962

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

RecruitingObservational study
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Feb 10, 2025 · NCT06817395

Idiopathic Thrombocytopenic Purpura trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.